carmustine and busulfan

carmustine has been researched along with busulfan in 70 studies

Research

Studies (70)

TimeframeStudies, this research(%)All Research%
pre-199016 (22.86)18.7374
1990's17 (24.29)18.2507
2000's17 (24.29)29.6817
2010's18 (25.71)24.3611
2020's2 (2.86)2.80

Authors

AuthorsStudies
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Lombardo, F; Obach, RS; Waters, NJ1
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP1
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Reissmann, KR; Udupa, KB2
Lohrmann, HP2
Marsh, JC1
Morley, AA; Trainor, KJ1
DeGregorio, MW; Rappeport, JM; Smith, BR; Wiebe, VJ1
Matthay, RA; Twohig, KJ1
Mandelli, F; Meloni, G1
Gomis, F; Javier Rafecas, F; Lorenzo, IJ; Martín-Aragonés, G; Martínez, JA; Marty, ML; Sanz, GF; Sanz, MA; Sayas, MJ1
Frome, E; Godfrey, G; Lindenschmidt, RC; Witschi, H1
Elfenbein, GJ; Owens, AH; Sensenbrenner, LL; Zawatzsky, LS1
Collis, CH1
Gamsu, G; Putman, CE; Sostman, HD1
Comis, RL; Ginsberg, SJ1
Bargon, G1
Beschorner, WE; Boitnott, JK; Pino, J; Santos, GW; Tutschka, PJ1
Cornbleet, MA; Leonard, RC; Smyth, JF1
Cohen, GI; Greenberger, JS; Sakakeeny, MA1
Allen, PD; Castenskiold, EC; Coldwell, RD; Collins, PW; Goldstone, AH; Kelsey, SM; Makin, HL; Newland, AC; Side, LE1
Crowther, D; Ghielmini, M; Morgenstern, GR; Pettengell, R; Radford, JA; Scheid, C; Stern, PL1
Barnett, MJ; Klingemann, HG; Nantel, SH; Phillips, GL; Reece, DE; Shepherd, JD; Spinelli, JJ; Sutherland, HJ1
Bout, M; Brémond, JL; Dayan, A; Delain, M; Domenech, J; Gihana, E; Linassier, C; Petit, A; Petitdidier, C; Truglio, D1
Duława, J; Franek, E; Hołowiecki, J; Kokot, F; Markiewicz, M; Wacławik, A; Wiecek, A; Wojnar, J1
Fujioka, K; Funabiki, T; Ikuta, K; Kai, S; Kajigaya, Y; Matsuyama, S; Sakai, H; Sekiguchi, H; Sumita, H; Takahashi, H1
Bulova, SI; Ciobanu, N; Cooper, BW; Creger, RJ; Crilley, P; Fox, RM; Gucalp, R; Lazarus, H; Shina, DC; Topolsky, D1
Ferrara, J; Hellman, S; Hemman, S; Mauch, P; Montgomery, M; Neben, S1
Andrews, F; Bolwell, B; Collins, R; Fay, J; LeFever, A; Levitt, D; List, A; Nemunaitis, J; Pallansch, P; Resta, D; Rosenfeld, CS; Schuster, MW; Taylor, R1
Navarra, P; Preziosi, P1
Abella, E; Adams, PT; al-Katib, A; Dragovic, J; Du, W; Janakiraman, N; Karanes, C; Raman, SB; Ratanatharathorn, V; Sensenbrenner, L; Silver, SM; Uberti, J; Varterasian, M1
Buckner, CD; Rhinehart, S; Schwartzberg, L; Weaver, CH; West, J; West, WH; Zhen, B1
Chen, PM; Chiou, TJ; Fang, FS; Hsieh, RK; Liu, JH; Tung, SL; Tzeng, CH; Wang, WS; Yen, CC1
Bigner, DD; Coggins, CA; Colvin, OM; Elion, GB; Friedman, HS; Hare, CB; Houghton, PJ; Keir, S1
Guest, I; Uetrecht, J1
Bhagwati, N; Horton, C; Kulkarni, S; Mainwaring, P; Mehta, J; Pandha, H; Powles, R; Singhal, S; Sirohi, B; Treleaven, J1
Blokland, I; Boudewijn, A; Down, JD; Margison, GP; McGown, AT; Ploemacher, RE; Watson, AJ; Westerhof, GR; Wood, M1
Kashyap, A; Snowden, J1
Cavenagh, J; Chopra, R; Clark, FJ; Culligan, D; Davies, A; Fuller, S; Hunt, L; Hunter, A; Littlewood, T; Lush, R; Marks, DI; Marsh, J; Milligan, DW; Parker, A; Schey, S; Smith, GM; Towlson, K; Vandenberghe, E; Williams, CD; Yin, J1
McCune, JS; Slattery, JT1
Fouillard, L; Frassoni, F; Gorin, NC; Labopin, M; Meloni, G; Polge, E1
Bates, SE; Holbeck, SL; Kohlhagen, G; Medina-Perez, W; Mertins, SD; Myers, TG; Pommier, Y; Wang, E1
Andresen, S; Ball, E; Bolwell, B; Cook, D; Kalaycio, M; Kuczkowski, E; Pohlman, B; Rybicki, L; Sobecks, R1
Rao, PS1
Alapetite, C; Anract, P; Babinet, A; Barthier, S; de Pinieux, G; Laurence, V; Palangié, T; Pierga, JY; Pouillart, P1
Horvath, N; Keefe, D; Lees, J1
Ades, L; Attal, M; Bernard, M; Blaise, D; Bordigoni, P; Bourhis, JH; Cassuto, JP; Chevalier, P; Deconinck, E; Facon, T; Garban, F; Ifrah, N; Kuentz, M; Lioure, B; Michallet, M; Milpied, N; Porcher, R; Renaud, M; Socié, G; Tabrizi, R; Tilly, H; Vernant, JP; Vigouroux, S1
Bensinger, WI; Gooley, T; Gopal, AK; Holmberg, L; Maloney, D; Press, O; Zaucha, R1
Huh, J; Kim, JE; Kim, S; Kim, SW; Lee, DH; Lee, JS; Park, CJ; Suh, C; Yoo, C1
Choma, M; Chybicka, A; Cornish, J; Gorczyńska, E; Grund, G; Kowalczyk, JR; Peters, C; Sykora, KW; Wachowiak, J1
Angelopoulou, MK; Beris, P; Constantinou, N; Dervenoulas, J; Diamantopoulos, P; Dimopoulos, MA; Dimou, M; Economopoulou, C; Economopoulou, P; Efthimiou, A; Georgiou, G; Kalpadakis, C; Katsigiannis, A; Korkolopoulou, P; Kotsianidis, I; Kyrtsonis, MC; Levidou, G; Meletis, J; Panayiotidis, P; Pangalis, GA; Papageorgiou, SG; Pappa, V; Tsirigotis, P; Vassilakopoulos, TP1
Ahmed, AB; Bruserud, O; Hatfield, KJ; Kittang, AO; Reikvam, H; Sjo, M; Tvedt, TH1
Chung, JS; Kim, H; Kim, JS; Lee, GW; Lee, HS; Lee, WS; Shin, HJ; Song, MK; Yhim, HY1
Berritta, D; Cupri, A; Fauci, AL; Leotta, S; Milone, G; Parisi, M; Spina, P; Tripepi, G1
Akpek, G; Aljurf, M; Artz, A; Bredeson, CN; Chen, YB; Cooke, KR; Ho, VT; Lane, AA; Lazarus, HM; Logan, B; McCarthy, P; Olsson, R; Pasquini, MC; Saber, W; Zhu, X1
Abela, EM; Anagnostopoulos, A; Apostolou, C; Baliakas, P; Batsis, I; Douka, V; Iskas, M; Kaloyannidis, P; Karypidis, K; Konstantinou, V; Kouvatseas, G; Mallouri, D; Marvaki, A; Sakellari, I; Smias, C; Sotiropoulos, D; Yannaki, E1
Ai, W; Bence-Bruckler, I; Bierman, P; Braunschweig, I; Chen, AI; Comeau, T; Costa, LJ; Craig, M; Fay, JW; Flinn, I; Flowers, CR; Freytes, CO; Horwitz, ME; Kato, K; Laneuville, P; Le-Rademacher, J; Lill, M; Mason, J; Mineishi, S; Pasquini, MC; Pulsipher, MA; Rodriguez, TE; Rondelli, D; Shea, TC; Shore, TB; Smith, AJ; Vaughan, W; Waller, EK; Wang, Y; Xu, C; Yeager, AM; Yeh, RF1
Ahmed, S; Alousi, A; Anderlini, P; Andersson, BS; Champlin, R; Dabaja, B; Fanale, M; Gulbis, A; Hosing, C; Jones, RB; Kebriaei, P; Ma, J; Milgrom, S; Myers, A; Nieto, Y; Oki, Y; Pinnix, C; Popat, U; Qazilbash, M; Shpall, EJ; Thall, PF; Timmons, M; Valdez, BC1
Fauble, V; Hogan, WJ; Jain, T; Khera, N; Kunze, KL; Leis, JF; Mesa, RA; Noel, P; Palmer, J; Partain, DK; Patnaik, MS; Roy, V; Slack, JL; Sproat, LZ; Temkit, M1
Abounader, D; Andritsos, L; Benson, DM; Bolwell, B; Dean, R; Devine, SM; Efebera, YA; Elder, P; Hill, B; Hofmeister, CC; Jagadeesh, D; Jaglowski, S; Kalaycio, M; Majhail, NS; Penza, S; Pohlman, B; Rosko, A; Sharma, N; Singer, S; Sobecks, R; Vasu, S; William, BM; Zhao, Q1
de Lima, VCC; Filho, JS; Germano, JN; Matias Vieira, GM; Moura, FL; Sapelli, J1
Abraham, J; Agbetiafa, K; Ahle, G; Bonmati, C; Bouabdallah, K; Bouabdallah, R; Bourget, P; Casasnovas, O; Charron, C; Chauchet, A; Chinot, O; Choquet, S; Cornillon, J; Damaj, G; Delwail, V; Dorvaux, V; Fabbro, M; Fornecker, LM; Ghesquières, H; Giordan, Q; Gressin, R; Gyan, E; Hoang-Xuan, K; Houillier, C; Houot, R; Jabeur, W; Jardin, F; Le Garff-Tavernier, M; Malaise, D; Marolleau, JP; Moluçon-Chabrot, C; Morschhauser, F; Nichelli, L; Oberic, L; Peyrade, F; Plessier, A; Roland, V; Schenone, L; Schmitt, A; Soussain, C; Taillandier, L; Tanguy, ML; Tempescul, A; Thieblemont, C; Touitou, V; Ursu, R; Wantz-Mézières, S; Waultier-Rascalou, A; Willems, L1

Reviews

13 review(s) available for carmustine and busulfan

ArticleYear
The effects of cancer chemotherapeutic agents on normal hematopoietic precursor cells: a review.
    Cancer research, 1976, Volume: 36, Issue:6

    Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Asparaginase; Benzamides; Busulfan; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Drug Evaluation, Preclinical; Erythrocytes; Fluorouracil; Hematopoietic Stem Cells; Humans; Hydroxyurea; Lomustine; Methotrexate; Nitrogen Mustard Compounds; Spleen; Vinca Alkaloids

1976
Pharmacology of agents used in bone marrow transplant conditioning regimens.
    Critical reviews in oncology/hematology, 1992, Volume: 13, Issue:3

    Topics: Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Carmustine; Hematopoiesis; Humans; Immunosuppressive Agents; Melphalan; Whole-Body Irradiation

1992
Pulmonary effects of cytotoxic agents other than bleomycin.
    Clinics in chest medicine, 1990, Volume: 11, Issue:1

    Topics: Antineoplastic Agents; Bleomycin; Busulfan; Carmustine; Cyclophosphamide; Humans; Lomustine; Methotrexate; Mitomycins; Pulmonary Fibrosis; Vinblastine; Vindesine

1990
Lung damage from cytotoxic drugs.
    Cancer chemotherapy and pharmacology, 1980, Volume: 4, Issue:1

    Topics: Antineoplastic Agents; Azathioprine; Bleomycin; Busulfan; Carmustine; Chlorambucil; Cyclophosphamide; Drug Therapy, Combination; Humans; Lung; Melphalan; Mercaptopurine; Methotrexate; Mitomycins; Oxygen Inhalation Therapy; Pneumonia; Procarbazine; Radiation Injuries

1980
Review: diagnosis of chemotherapy lung.
    AJR. American journal of roentgenology, 1981, Volume: 136, Issue:1

    Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bleomycin; Busulfan; Carmustine; Cyclophosphamide; Female; Humans; Lomustine; Lung Diseases; Lung Neoplasms; Male; Mercaptopurine; Methotrexate; Middle Aged; Pulmonary Fibrosis; Radiography

1981
The problem of permanent bone marrow damage after cytotoxic drug treatment.
    Oncology, 1984, Volume: 41, Issue:3

    Topics: Animals; Antineoplastic Agents; Bone Marrow Diseases; Busulfan; Carmustine; Cell Division; Cell Survival; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Hematopoiesis; Hematopoietic Stem Cells; Humans; Melphalan; Semustine; Time Factors

1984
High-dose alkylating agent therapy: a review of clinical experiences.
    Cancer drug delivery, 1984,Summer, Volume: 1, Issue:3

    Topics: Alkylating Agents; Busulfan; Carcinoma, Bronchogenic; Carmustine; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Mechlorethamine; Melphalan; Neoplasms; Ovarian Neoplasms; Testicular Neoplasms

1984
Regimen-related acute toxicities: pathophysiology, risk factors, clinical evaluation and preventive strategies.
    Bone marrow transplantation, 1994, Volume: 14 Suppl 4

    Topics: Acute Disease; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carboplatin; Carmustine; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Cyclophosphamide; Cystitis; Female; Hepatic Veno-Occlusive Disease; Humans; Incidence; Leukemia, Myeloid; Liver; Lung Diseases, Interstitial; Lymphoma; Male; Methotrexate; Retrospective Studies; Risk Factors; Whole-Body Irradiation

1994
Drugs toxic to the bone marrow that target the stromal cells.
    Immunopharmacology, 2000, Volume: 46, Issue:2

    Topics: Animals; Benzene; Bone Marrow Cells; Busulfan; Carmustine; Ceftazidime; Cyclophosphamide; Doxorubicin; Humans; Stromal Cells

2000
Considerations in the selection of an appropriate conditioning regimen for the treatment of rheumatoid arthritis by autologous peripheral blood stem cell transplantation.
    The Journal of rheumatology. Supplement, 2001, Volume: 64

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Melphalan; Podophyllotoxin; Radiotherapy, Adjuvant; Transplantation Conditioning; Transplantation, Autologous; Vidarabine

2001
Pharmacological considerations of primary alkylators.
    Cancer treatment and research, 2002, Volume: 112

    Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; Carboplatin; Carmustine; Cisplatin; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Thiotepa

2002
Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor.
    American journal of clinical oncology, 2005, Volume: 28, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Busulfan; Carmustine; Cisplatin; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Life Tables; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prognosis; Retrospective Studies; Risk Factors; Sarcoma, Ewing; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vincristine

2005
High-dose etoposide in allogeneic stem cell transplantation.
    Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:6

    Topics: Adenine Nucleotides; Anthracyclines; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Busulfan; Carboplatin; Carmustine; Clinical Trials as Topic; Clofarabine; Cyclophosphamide; Dose Fractionation, Radiation; Drug Administration Schedule; Etoposide; Humans; Ifosfamide; Leukemia; Leukemia, Myeloid, Acute; Lomustine; Mucositis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiotherapy, Adjuvant; Severity of Illness Index; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Whole-Body Irradiation

2012

Trials

13 trial(s) available for carmustine and busulfan

ArticleYear
[Autotransplantation in acute nonlymphoid leukemia].
    Haematologica, 1991, Volume: 76 Suppl 3

    Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Humans; Leukemia, Myeloid, Acute; Remission Induction; Transplantation, Autologous

1991
[High-dose busulfan, VP-16 and ACNU therapy with stem cell transplantation for the treatment of children with acute leukemia].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1993, Volume: 34, Issue:5

    Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmustine; Child; Child, Preschool; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Male; Nimustine

1993
Comparison of four cytokine regimens for mobilization of peripheral blood stem cells: IL-3 alone and combined with GM-CSF or G-CSF.
    Bone marrow transplantation, 1996, Volume: 17, Issue:2

    Topics: Adult; Bone Marrow; Breast Neoplasms; Busulfan; Carboplatin; Carmustine; Cyclophosphamide; Drug Administration Schedule; Drug Synergism; Etoposide; Female; Graft Survival; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Interleukin-3; Leukapheresis; Leukemia; Leukocyte Count; Lymphoma; Male; Middle Aged; Neutrophils; Prospective Studies; Thiotepa; Whole-Body Irradiation

1996
Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant.
    American journal of clinical oncology, 1997, Volume: 20, Issue:5

    Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transplantation; Busulfan; Carmustine; Cause of Death; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Whole-Body Irradiation

1997
High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
    Bone marrow transplantation, 1998, Volume: 21, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Survival Rate; Transplantation, Autologous

1998
Navoban (tropisetron, ICS 205-930) and dexamethasone combination in the prevention of vomiting for patients receiving preconditioning high-dose chemotherapy before marrow transplantation.
    Japanese journal of clinical oncology, 1998, Volume: 28, Issue:2

    Topics: Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmustine; Child; Cyclophosphamide; Cytarabine; Dexamethasone; Dizziness; Drug Therapy, Combination; Female; Headache; Heartburn; Humans; Indoles; Leukemia; Male; Melphalan; Middle Aged; Multiple Myeloma; Podophyllotoxin; Transplantation Conditioning; Tropisetron; Vomiting; Whole-Body Irradiation

1998
The role of autologous transplantation in patients with multiple myeloma aged 65 years and over.
    Bone marrow transplantation, 2000, Volume: 25, Issue:5

    Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Chemical and Drug Induced Liver Injury; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Graft Survival; Heart Diseases; Hematopoietic Stem Cell Mobilization; Hospitalization; Humans; Interferons; Kidney Diseases; Male; Matched-Pair Analysis; Melphalan; Methylprednisolone; Middle Aged; Multiple Myeloma; Neutropenia; Neutrophils; Platelet Count; Recurrence; Sepsis; Survival Rate; Thrombocytopenia; Transplantation, Autologous; Vincristine

2000
CD8+ T-cell-depleted, matched unrelated donor, allogeneic bone marrow transplantation for advanced AML using busulfan-based preparative regimens.
    Bone marrow transplantation, 2005, Volume: 35, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmustine; CD8-Positive T-Lymphocytes; Cyclophosphamide; Etoposide; Female; Graft Survival; Graft vs Host Disease; Histocompatibility; Histocompatibility Testing; Humans; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Middle Aged; Salvage Therapy; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome

2005
Palifermin for oral mucositis in the high-dose chemotherapy and stem cell transplant setting: the Royal Adelaide Hospital Cancer Centre experience.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2006, Volume: 14, Issue:6

    Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cancer Care Facilities; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Drug Eruptions; Female; Fibroblast Growth Factor 7; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Male; Melphalan; Middle Aged; Podophyllotoxin; Primary Prevention; Severity of Illness Index; South Australia; Stomatitis; Time Factors; Transplantation Conditioning; Treatment Outcome

2006
BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.
    Leukemia research, 2011, Volume: 35, Issue:2

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult

2011
Treosulfan-based preparative regimens for allo-HSCT in childhood hematological malignancies: a retrospective study on behalf of the EBMT pediatric diseases working party.
    Bone marrow transplantation, 2011, Volume: 46, Issue:12

    Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Etoposide; Female; Hematologic Neoplasms; Humans; Infant; Male; Melphalan; Retrospective Studies; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2011
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016, Volume: 22, Issue:7

    Topics: Adult; Aged; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Melphalan; Middle Aged; North America; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous

2016
Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2018, Volume: 24, Issue:8

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Deoxycytidine; Etoposide; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Melphalan; Middle Aged; Salvage Therapy; Survival Analysis; Transplantation, Autologous; Young Adult

2018

Other Studies

44 other study(ies) available for carmustine and busulfan

ArticleYear
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
    Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21

    Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:4

    Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water

2010
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
    Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10

    Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding

2012
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
In vivo erythropoietin requirements of regenerating erythroid progenitors (BFU-e, CFU-e) in bone marrow of mice.
    Blood, 1979, Volume: 53, Issue:6

    Topics: Animals; Bone Marrow Cells; Busulfan; Carmustine; Erythrocytes; Erythropoiesis; Erythropoietin; Female; Hematopoietic Stem Cells; Mice; Polycythemia

1979
Tolerance of hemopoiesis for repeated cytotoxic drug therapy.
    Blut, 1979, Volume: 39, Issue:4

    Topics: Animals; Antineoplastic Agents; Busulfan; Carmustine; Hematopoiesis; Hematopoietic Stem Cells; Humans

1979
Screening of cytotoxic drugs for residual bone marrow damage.
    Journal of the National Cancer Institute, 1976, Volume: 57, Issue:6

    Topics: Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Diseases; Busulfan; Carmustine; Cell Survival; Cyclophosphamide; Drug Evaluation, Preclinical; Female; Fluorouracil; Hematopoietic Stem Cells; Mercaptopurine; Methotrexate; Mice; Mice, Inbred BALB C; Vinblastine

1976
[Treatment of acute adult myeloblastic leukemia with intensive chemotherapy].
    Sangre, 1986, Volume: 31, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Combinations; Drug Evaluation; Female; Humans; Leukemia, Myeloid, Acute; Male; Meningeal Neoplasms; Mercaptopurine; Methotrexate; Middle Aged; Mitoguazone; Prednisone; Thioguanine; Vincristine

1986
Pulmonary toxicity of cytostatic drugs: cell kinetics.
    Fundamental and applied toxicology : official journal of the Society of Toxicology, 1987, Volume: 8, Issue:2

    Topics: Animals; Autoradiography; Busulfan; Carmustine; Cell Division; Cyclophosphamide; DNA Replication; Kinetics; Lung; Male; Mice; Mice, Inbred BALB C; Oleic Acid; Oleic Acids; Thymidine; Tritium

1987
Comparative effects of selected cytotoxic agents on transplanted hematopoietic cells.
    Transplantation, 1972, Volume: 14, Issue:3

    Topics: Animals; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Carmustine; Cell Survival; Cortisone; Cyclophosphamide; Graft vs Host Reaction; Immunosuppression Therapy; Mercaptopurine; Methotrexate; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Time Factors; Transplantation Immunology; Transplantation, Homologous; Vincristine

1972
Acceleration of granulopoietic recovery by androgenic steroids in mice made neutropenic by cytotoxic drugs.
    Cancer research, 1974, Volume: 34, Issue:10

    Topics: Agranulocytosis; Androgens; Animals; Bone Marrow; Busulfan; Carmustine; Cell Division; Clone Cells; Cyclophosphamide; Female; Granulocytes; Hematopoiesis; Mice; Nandrolone; Neutropenia; Oxymetholone; Spleen; Stimulation, Chemical; Testosterone; Vinblastine

1974
The pulmonary toxicity of antineoplastic agents.
    Seminars in oncology, 1982, Volume: 9, Issue:1

    Topics: Age Factors; Aged; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Bleomycin; Busulfan; Carmustine; Dogs; Dose-Response Relationship, Drug; Haplorhini; Humans; Mitomycin; Mitomycins; Pulmonary Alveoli; Pulmonary Fibrosis; Radiography; Rodentia; Time Factors

1982
[Drug-induced changes in the lungs].
    Rontgen-Blatter; Zeitschrift fur Rontgen-Technik und medizinisch-wissenschaftliche Photographie, 1984, Volume: 37, Issue:7

    Topics: Albumins; Bleomycin; Busulfan; Carmustine; Drug-Related Side Effects and Adverse Reactions; Humans; Iodized Oil; Lung; Lung Diseases; Nitrofurantoin; Radiography

1984
Pathology of the liver with bone marrow transplantation. Effects of busulfan, carmustine, acute graft-versus-host disease, and cytomegalovirus infection.
    The American journal of pathology, 1980, Volume: 99, Issue:2

    Topics: Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Carmustine; Cytomegalovirus Infections; Graft vs Host Reaction; Humans; Leukemia; Liver; Retrospective Studies; Transplantation, Homologous

1980
The development of a system for study of bone marrow transplantation in vitro: effects of X-irradiation dose rate and chemotherapeutic agents on the isolated bone marrow microenvironment.
    Kroc Foundation series, 1984, Volume: 18

    Topics: Animals; Bone Marrow; Bone Marrow Cells; Busulfan; Carmustine; Cell Communication; Cells, Cultured; Colony-Forming Units Assay; Culture Techniques; Doxorubicin; Female; Hematopoiesis; Hematopoietic Stem Cells; Interleukin-3; Lymphokines; Melphalan; Mice; Mice, Inbred Strains

1984
Functional hyperactivity of monocytes after bone marrow transplantation: possible relevance for the development of post-transplant complications or relapse.
    Bone marrow transplantation, 1995, Volume: 15, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopterins; Bone Marrow Transplantation; Busulfan; Carmustine; Cells, Cultured; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Susceptibility; Female; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Humans; Leukemia; Lymphoma; Male; Melphalan; Middle Aged; Monocytes; Neopterin; Podophyllotoxin; Respiratory Burst; Superoxides; Tumor Necrosis Factor-alpha; Whole-Body Irradiation

1995
Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
    Bone marrow transplantation, 1995, Volume: 15, Issue:6

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Diseases; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Killer Cells, Lymphokine-Activated; Killer Cells, Natural; Leukapheresis; Lymphocyte Count; Lymphocyte Subsets; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Melphalan; Mesna; Middle Aged; Podophyllotoxin; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Time Factors; Treatment Outcome; Vincristine

1995
Prolonged impairment of hematopoiesis after high-dose therapy followed by autologous bone marrow transplantation.
    Blood, 1995, Jun-01, Volume: 85, Issue:11

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Busulfan; Carmustine; Cell Count; Child; Child, Preschool; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoiesis; Hematopoietic Cell Growth Factors; Humans; Male; Melphalan; Methotrexate; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplasms; Prognosis; Radiation Injuries; Treatment Outcome; Vincristine; Whole-Body Irradiation

1995
[Excretion of beta-2-microglobulin and Tamm-Horsfall protein in patients undergoing a conditioning regimen before bone marrow transplantation].
    Polskie Archiwum Medycyny Wewnetrznej, 1994, Volume: 92, Issue:5

    Topics: Adjuvants, Immunologic; Adult; beta 2-Microglobulin; Bone Marrow Transplantation; Busulfan; Carmustine; Cyclophosphamide; Drug Therapy, Combination; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kidney Tubules; Male; Mucoproteins; Preoperative Care; Uromodulin

1994
Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies.
    Seminars in oncology, 1993, Volume: 20, Issue:4 Suppl 4

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Etoposide; Humans; Lymphoma; Middle Aged; Survival Analysis; Treatment Outcome

1993
Hematopoietic stem cell deficit of transplanted bone marrow previously exposed to cytotoxic agents.
    Experimental hematology, 1993, Volume: 21, Issue:1

    Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Hematopoiesis; Hematopoietic Stem Cells; Leukocyte Count; Male; Mice; Mice, Inbred C3H; Time Factors; Whole-Body Irradiation

1993
Disruptions of the hypothalamo-pituitary-adrenal axis increase anticancer drug lethality in the rat.
    Toxicology letters, 1997, May-16, Volume: 91, Issue:3

    Topics: Adrenalectomy; Animals; Antineoplastic Agents; Busulfan; Carmustine; Corticosterone; Cosyntropin; Cyclophosphamide; Fluorouracil; Hypophysectomy; Hypothalamo-Hypophyseal System; Male; Pituitary-Adrenal System; Rats; Rats, Wistar; Vindesine

1997
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
    Cancer chemotherapy and pharmacology, 1998, Volume: 41, Issue:6

    Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Busulfan; Camptothecin; Carmustine; Child; Cyclophosphamide; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Ependymoma; Female; Glioma; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Topoisomerase I Inhibitors; Transplantation, Heterologous

1998
O6-Benzylguanine potentiates BCNU but not busulfan toxicity in hematopoietic stem cells.
    Experimental hematology, 2001, Volume: 29, Issue:5

    Topics: Alkylation; Animals; Antineoplastic Agents, Alkylating; Busulfan; Carmustine; Cell Line; CHO Cells; Coculture Techniques; Colony-Forming Units Assay; Cricetinae; Cricetulus; DNA Damage; DNA Repair; Erythroid Precursor Cells; Fibroblasts; Guanine; Hematopoietic Stem Cells; Humans; Male; Mice; Mice, Inbred C57BL; O(6)-Methylguanine-DNA Methyltransferase; Stromal Cells; Transfection

2001
The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation.
    Blood, 2002, Nov-01, Volume: 100, Issue:9

    Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclosporine; Cytarabine; Data Collection; Etoposide; Female; Follow-Up Studies; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine

2002
Comparison of BAVC to BuCy regimens in autologous stem cell transplantation for adult patients with acute myeloid leukemia.
    Haematologica, 2004, Volume: 89, Issue:1

    Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Combinations; Etoposide; Female; Humans; Leukemia, Erythroblastic, Acute; Leukemia, Megakaryoblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Transplantation, Autologous

2004
In vitro evaluation of dimethane sulfonate analogues with potential alkylating activity and selective renal cell carcinoma cytotoxicity.
    Molecular cancer therapeutics, 2004, Volume: 3, Issue:7

    Topics: Alkylating Agents; Animals; Bromodeoxyuridine; Busulfan; Carcinoma, Renal Cell; Carmustine; Cell Cycle; DNA Damage; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Inhibitory Concentration 50; Kidney Neoplasms; Mesylates; Rats; Tumor Suppressor Protein p53; Yeasts

2004
Nephrotic syndrome in patients with peripheral blood stem cell transplant.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2005, Volume: 45, Issue:4

    Topics: Acute Kidney Injury; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytomegalovirus Infections; Etoposide; Glomerulonephritis, Membranous; Graft vs Host Disease; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Methotrexate; Middle Aged; Multiple Myeloma; Nephrotic Syndrome; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Prednisone; Rituximab; Sepsis; Staphylococcal Infections; Tacrolimus; Transplantation Conditioning

2005
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
    Haematologica, 2007, Volume: 92, Issue:5

    Topics: Adult; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Data Collection; Disease-Free Survival; Etoposide; Female; France; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Analysis; Survival Rate; T-Lymphocytes; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation

2007
High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic cell transplantation in malignant lymphoma.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:10

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Drug Evaluation; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Retrospective Studies; Thiotepa; Transplantation, Autologous

2008
Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
    Hematological oncology, 2013, Volume: 31, Issue:1

    Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Carmustine; Combined Modality Therapy; Cranial Irradiation; Cyclophosphamide; Cytarabine; Doxorubicin; Female; Humans; Incidence; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Mediastinal Neoplasms; Methotrexate; Methylprednisolone; Middle Aged; Prednisone; Proportional Hazards Models; Retrospective Studies; Risk Factors; Rituximab; Salvage Therapy; Stem Cell Transplantation; Thiotepa; Vincristine; Young Adult

2013
Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma.
    Leukemia & lymphoma, 2014, Volume: 55, Issue:11

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Remission Induction; Retrospective Studies; Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult

2014
Palifermin reduces infection rate and hyperfibrinogenemia in patients treated with high-dose chemotherapy based on beam or BU-thiothepa.
    Bone marrow transplantation, 2014, Volume: 49, Issue:9

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Female; Fibrinogen; Fibroblast Growth Factor 7; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infection Control; Male; Melphalan; Middle Aged; Podophyllotoxin; Retrospective Studies; Thiotepa; Transplantation Conditioning; Young Adult

2014
Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2015, Volume: 21, Issue:6

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Drug Administration Schedule; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Registries; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Whole-Body Irradiation

2015
Carmustine, etoposide, cytarabine and melphalan versus a newly designed intravenous busulfan-based Busulfex, etoposide and melphalan conditioning regimen for autologous hematopoietic cell transplant: a retrospective matched-pair analysis in advanced Hodgk
    Leukemia & lymphoma, 2015, Volume: 56, Issue:11

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Matched-Pair Analysis; Melphalan; Middle Aged; Neoplasm Staging; Podophyllotoxin; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Young Adult

2015
Comparison of reduced intensity conditioning regimens used in patients undergoing hematopoietic stem cell transplantation for myelofibrosis.
    Bone marrow transplantation, 2019, Volume: 54, Issue:2

    Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Carmustine; Chimerism; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Primary Myelofibrosis; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine

2019
BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:6

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Cyclophosphamide; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Podophyllotoxin; Transplantation Conditioning; Young Adult

2019
BuCyE can safely replace BEAM as a conditioning regimen for autologous stem cell transplantation in the treatment of refractory and relapsed lymphomas.
    Leukemia research, 2021, Volume: 110

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate; Transplantation Conditioning; Transplantation, Autologous; Young Adult

2021
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
    Bone marrow transplantation, 2022, Volume: 57, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmustine; Central Nervous System; Central Nervous System Neoplasms; Cyclophosphamide; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Neoplasm Recurrence, Local; Prospective Studies; Thiotepa; Transplantation, Autologous; Treatment Outcome

2022